HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nonprofit Pharmaceutical Companies

496.720

-5.792-1.15%

Number of Gainers:6

Number of Losers:25

Number of Flat:2

PE:- -

High:507.303

Open:502.573

Low:495.158

Close:502.512

Volume:81.75M

Turnover:1.81B

Market Cap:315.27B

Float Cap:280.61B

Loading ...

Milestone Pharmaceuticals Says NMPA Approval Triggers $2 Mln Milestone Payment to the Co

Everest Medicines Gets China Nod for CARDAMYST Application

MT Newswires Live

ZYLOXTB (02190) Allocates HK$1.12 Million for Share Buyback on September 3

Zylox-Tonbridge Files HKEX Next-Day Disclosure Return on Share Buyback

Everest Medicines Says China NMPA Approves Cardamyst Nasal Spray for PSVT Conversion in Adults

Everest Medicines - Nmpa Approves Cardamyst (Etripamil) Nda for Psvt in Adults in China

THOMSON REUTERS

Ni Xin Boosts Stake in Edding Genor with 150,000 Share Purchase

GENFLEET-B Allocates HK$546,400 to Buy Back 20,000 Shares on September 3

Navigating the Investment Landscape Amid the Innovative Drug Surge

CMS Secures NMPA Nod for Ruxolitinib Cream's Expanded Use in Atopic Dermatitis

Apichope's Gout Drug Candidate Meets Primary Goal in Late-Stage China Trial

EVEREST MED's pioneering cardiovascular treatment receives green light in China, introducing the first and only on-demand rescue therapy for adults with PSVT

AH Premium Rankings Update: September 3 Market Close

Yinchuan Market Regulators Roll Out Comprehensive Measures to Implement Revised Medical Device Production Quality Standards

HK Stock Alert: Keymed Bio Surges Over 3% on Landmark Licensing Deal with Aeira

Keymed Biosciences Climbs on Licensing Deal with Aeira Pte

Clinical Data Readouts Take Center Stage as Chinese Biotech Firms Surge; CSPC Pharma Climbs Over 4% While Huabao's HK Biotech ETF Holds Key Support

Keymed Biosciences Signs Licensing Deal for Kangyueda in 18 Markets

Is CStone Pharmaceuticals (SEHK:2616) Fully Valued On Interim Results And CS2009 Progress?

Simply Wall St.

Akeso - Ivonescimab Meets Os Key Secondary Endpoint in Harmoni-2 Study

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/BK1574/news?page=10"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":496.71994,"timestamp":1789459707407,"preClose":502.51205,"halted":0,"volume":81750325,"delay":0,"changeRate":-0.011526,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":-5.792114,"latestTime":"09-15 16:00:00","open":502.57327,"high":507.303,"low":495.15784,"amount":1806018702,"amplitude":0.024169,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789522200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789435800000,1789444800000],[1789448400000,1789459200000]],"pbRate":3.744174,"peRate":166.585651,"turnoverRate":0.00304,"increases":7,"decrements":24,"flats":1,"marketCap":315273116400,"floatMarketCap":280608949080},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":507.303,"amplitude":0.024169,"preClose":502.51205,"low":495.15784,"pbRate":"3.744174","latestPrice":496.71994,"volume":81750325,"delay":0,"open":502.57327,"prevYearClose":556.26263,"prevWeekClose":483.155,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":518.573,"twentyDayClose":502.603,"sixtyDayClose":431.958,"secType":"PLATE","market":"HK","turnoverRate":0.00304,"peRate":166.585651,"marketCap":315273116400,"floatMarketCap":280608949080,"timestamp":1789459707407,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":6,"down":25,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:10,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664480867","title":"Milestone Pharmaceuticals Says NMPA Approval Triggers $2 Mln Milestone Payment to the Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2664480867","media":"Reuters","labels":["corporation","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664480867?lang=en_us&edition=fundamental","pubTime":"2026-09-03 22:56","pubTimestamp":1788447419,"startTime":"0","endTime":"0","summary":"Sept 3 (Reuters) - Milestone Pharmaceuticals Inc::*MILESTONE PHARMACEUTICALS ANNOUNCES NMPA APPROVAL OF ETRIPAMIL NASAL SPRAY FOR PSVT IN CHINA, MARKING FIRST REGULATORY APPROVAL OF ETRIPAMIL OUTSIDE ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nRSD1Mvfn1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK4007","01952","MIST","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664874018","title":"Everest Medicines Gets China Nod for CARDAMYST Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2664874018","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664874018?lang=en_us&edition=fundamental","pubTime":"2026-09-03 20:40","pubTimestamp":1788439214,"startTime":"0","endTime":"0","summary":"Everest Medicines  obtained approval for the new drug application of CARDAMYST from China's National Medical Products Administration.The drug is for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia to sinus rhythm in adults, according to a Thursday Hong Kong bourse filing.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["01952","BK1574","BK1583","MDCO","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159831479","title":"ZYLOXTB (02190) Allocates HK$1.12 Million for Share Buyback on September 3","url":"https://stock-news.laohu8.com/highlight/detail?id=1159831479","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159831479?lang=en_us&edition=fundamental","pubTime":"2026-09-03 20:24","pubTimestamp":1788438277,"startTime":"0","endTime":"0","summary":"ZYLOXTB (02190) declared that on September 3, 2026, the company repurchased 52,500 shares at an aggregate cost of roughly HK$1.1219 million.The shares were bought back at a price range of HK$21.18 to HK$21.52 each.","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","02190","BK1574","BK1100","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664874561","title":"Zylox-Tonbridge Files HKEX Next-Day Disclosure Return on Share Buyback","url":"https://stock-news.laohu8.com/highlight/detail?id=2664874561","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664874561?lang=en_us&edition=fundamental","pubTime":"2026-09-03 20:17","pubTimestamp":1788437861,"startTime":"0","endTime":"0","summary":"Zylox-Tonbridge files HKEX next-day disclosure return on share buybackZylox-Tonbridge repurchased 52,500 H shares on Sept. 3, 2026 for treasury.Buyback price range HKD 21.18 to HKD 21.52; aggregate co","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL70MPxB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1100","BK1587","BK1574","BK1583","02190"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664087437","title":"Everest Medicines Says China NMPA Approves Cardamyst Nasal Spray for PSVT Conversion in Adults","url":"https://stock-news.laohu8.com/highlight/detail?id=2664087437","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664087437?lang=en_us&edition=fundamental","pubTime":"2026-09-03 20:15","pubTimestamp":1788437722,"startTime":"0","endTime":"0","summary":"Everest Medicines says China NMPA approves Cardamyst nasal spray for PSVT conversion in adultsChina’s NMPA cleared the NDA for CARDAMYST (etripamil) nasal spray to convert acute PSVT episodes to sinus","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDLbRghy4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1161","01952","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664871033","title":"Everest Medicines - Nmpa Approves Cardamyst (Etripamil) Nda for Psvt in Adults in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2664871033","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664871033?lang=en_us&edition=fundamental","pubTime":"2026-09-03 20:06","pubTimestamp":1788437196,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nFWN44V0KG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01952","BK1574","BK1583","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176154423","title":"Ni Xin Boosts Stake in Edding Genor with 150,000 Share Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=1176154423","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176154423?lang=en_us&edition=fundamental","pubTime":"2026-09-03 19:34","pubTimestamp":1788435274,"startTime":"0","endTime":"0","summary":"Recent data from the Hong Kong Stock Exchange reveals that on September 1, Ni Xin increased his holdings in EDDING GENOR (06998) by 150,000 shares at a price of HK$1.6489 per share, totaling...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","06998","BK1583","EWH","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101393084","title":"GENFLEET-B Allocates HK$546,400 to Buy Back 20,000 Shares on September 3","url":"https://stock-news.laohu8.com/highlight/detail?id=1101393084","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101393084?lang=en_us&edition=fundamental","pubTime":"2026-09-03 19:24","pubTimestamp":1788434654,"startTime":"0","endTime":"0","summary":"GENFLEET-B (02595) announced that on September 3, 2026, it spent HK$546,400 to repurchase 20,000 of its own shares.This buyback reflects the company's ongoing capital management strategy, as it...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02595","BK1515","09939","159938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135667303","title":"Navigating the Investment Landscape Amid the Innovative Drug Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=1135667303","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135667303?lang=en_us&edition=fundamental","pubTime":"2026-09-03 18:20","pubTimestamp":1788430837,"startTime":"0","endTime":"0","summary":"As the innovative drug sector gains momentum, investors are keenly eyeing opportunities that align with this upward trend. The recent formation of a MACD golden cross signal, a key technical...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBQ","BK1574","06978","159992","BK1161","LNGR","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176808711","title":"CMS Secures NMPA Nod for Ruxolitinib Cream's Expanded Use in Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=1176808711","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176808711?lang=en_us&edition=fundamental","pubTime":"2026-09-03 18:04","pubTimestamp":1788429862,"startTime":"0","endTime":"0","summary":"CMS (00867) has announced that its subsidiary, Demei Pharma, obtained approval from China's National Medical Products Administration (NMPA) on September 2, 2026, for the New Drug Application (NDA) of...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK4132","IBBQ","00867","SG9999015952.SGD","06978","BK1593","SG9999015945.SGD","IE00BVYPNP33.GBP","IE00BGHQDM52.EUR","AD","BK1191","159992","MEDX","LU2488822045.USD","SG9999004220.SGD","IPOS","LNGR","BK1161","SG9999015978.USD","IE00BYV24P56.USD","SG9999015986.USD","IE00BVYPNQ40.USD","IE00BMCWC346.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148282007","title":"Apichope's Gout Drug Candidate Meets Primary Goal in Late-Stage China Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1148282007","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148282007?lang=en_us&edition=fundamental","pubTime":"2026-09-03 17:50","pubTimestamp":1788429022,"startTime":"0","endTime":"0","summary":"Apichope Pharmaceutical Group Co.,Ltd. (300723.SZ) has announced that its wholly-owned subsidiary, Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd., recently obtained top-line data from a Phase...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","BK0239","06978","300723","MEDX","159992","LNGR","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152809628","title":"EVEREST MED's pioneering cardiovascular treatment receives green light in China, introducing the first and only on-demand rescue therapy for adults with PSVT","url":"https://stock-news.laohu8.com/highlight/detail?id=1152809628","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152809628?lang=en_us&edition=fundamental","pubTime":"2026-09-03 16:50","pubTimestamp":1788425447,"startTime":"0","endTime":"0","summary":"On September 3rd, Hong Kong-listed innovative drug developer EVEREST MED (01952) announced that China's National Medical Products Administration (NMPA) has approved the New Drug Application (NDA) for...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952","BK1574","HRTS","BK1161","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199507474","title":"AH Premium Rankings Update: September 3 Market Close","url":"https://stock-news.laohu8.com/highlight/detail?id=1199507474","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199507474?lang=en_us&edition=fundamental","pubTime":"2026-09-03 16:22","pubTimestamp":1788423720,"startTime":"0","endTime":"0","summary":"As of the close on September 3, NE ELECTRIC (00042), ZHEJIANG SHIBAO (01057), and HOLLY FUTURES (03678) occupy the top three positions in the AH premium rate rankings, with premium rates of 993.12%,...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0266512473.USD","LU1115378108.SGD","LU0449509016.USD","HK0000352291.HKD","IE00B031HY20.USD","BK1533","BK1544","LU0345780281.USD","LU2476274308.USD","LU0531970944.HKD","LU0502904849.HKD","IE0008368742.USD","BK1594","LU1282649810.SGD","LU2097828631.EUR","LU0165289439.USD","LU0228367735.SGD","LU1226287529.USD","LU0266512127.USD","LU0211977185.USD","LU1303224171.USD","02692","BK1202","BK1249","02701","LU1105468828.SGD","LU0456846285.SGD","LU0823426308.USD","LU0890818403.SGD","LU0737861699.HKD","LU2045819591.USD","LU1688375341.USD","02009","01877","LU0106252389.USD","HK0000306701.USD","LU1282649141.HKD","LU0082770016.USD","LU1880383366.USD","BK1163","HK0000352382.USD","LU0052750758.USD","LU0488056044.USD","BK1564","LU0096374516.USD","BK1560","LU0048580855.USD","02691","LU0228659784.USD","BK1214","LU0164939612.USD","LU1048596156.SGD","LU2394011477.USD","LU0210526637.USD","SG9999002828.SGD","SG9999001093.SGD","IE00BZ08YR35.GBP","LU0231483743.USD","BK1130","LU0254981946.USD","EWH","02338","LU1255011170.USD","LU0051755006.USD","LU0455707207.USD","LU0163747925.USD","LU1770034418.SGD","LU0417516738.SGD","03968","IE00BMCWC346.EUR","BK1562","01812","LU0229945570.USD","BK1149","00991","LU0329678337.USD","IE00BGHQDM52.EUR","LU0918141887.USD","BK1147","LU0543330483.HKD","IE0034224299.USD","LU0326950275.SGD","LU0359202008.SGD","BK1116","BK1514","SG9999004220.SGD","BK1191","BK1574","00042","LU0469268626.HKD","LU0244354667.USD","02846","06826","LU0871576103.HKD","BK1523","LU0531971595.HKD","LU0588546209.SGD","LU0417516902.SGD","LU0620787316.HKD","BK1551","LU0648948544.HKD","LU1813983027.USD","00187","SG9999002463.SGD","LU0320764599.SGD","IE00BVYPNQ40.USD","LU1366334578.USD","LU1188198961.HKD","00811","HK0000320264.USD","BK1583","LU2097828474.EUR","LU0821914370.USD","BK1521","LU0164865239.USD","HK0001040143.USD","399300","LU2097828714.EUR","BK1503","01349","LU1328277881.USD","LU0181495838.USD","LU0456854461.SGD","LU0862451753.SGD","00568","LU0868486357.SGD","SG9999014674.SGD","IE0032431581.USD","BK1506","00300","07233","BK1125","LU0516423091.SGD","LU0463099449.HKD","LU0307460666.USD","IE00BZ08YT58.USD","02475","LU1366334651.USD","BK1161","01033","LU0164880469.USD","06869","LU1282649067.USD","LU0314109678.HKD","LU1008478684.HKD","LU1961090484.USD","BK1141","LU0348766576.USD","BK1546","IE0008369823.USD","06185","LU0828237510.HKD","IE0031814852.USD","SG9999011746.SGD","LU2399975544.HKD","LU0634319403.HKD","IE00B031J352.USD","BK1144","BK1223","01057","LU0737861772.HKD","LU0348788117.USD","00553","BK1522","LU0886674414.USD","LU0072913022.USD","LU0067412154.USD","BK1105","LU0043850808.USD","BK1190","LU0214875030.USD","BK1237","IE00B5MMRT66.SGD","03143","LU0329678170.USD","LU1244550577.SGD","LU0061477393.USD","LU2264538146.SGD","LU0348805143.USD","IE00BYV24P56.USD","LU1282648689.USD","BK1563","LU0918141705.HKD","LU2778985437.USD","LU0149534421.HKD","LU1046422090.SGD","IE00B29SXG58.USD","LU0791590937.USD","LU1244550221.USD","BK1593","03328","LU0791591158.USD","BK1171","BK1576","LU0348814723.USD","LU0501845795.SGD","LU0269904917.USD","LU0348735423.USD","LU0140636845.USD","BK1505","LU0516423174.USD","LU0540923850.HKD","LU1808992512.USD","LU0708995583.HKD","LU0516422440.USD","LU0572944931.SGD","03759","LU0359201612.USD","LU0797268264.HKD","LU0128522157.USD","LU1831875114.USD","LU0029875118.USD","LU1960683339.HKD","LU1064131342.USD","BK1530","LU0828237940.HKD","BK1122","IE00B3M56506.USD","LU0149721374.USD","LU1481107354.HKD","03188","HK0000306685.HKD","LU0589944569.HKD","LU0320764755.SGD","LU0359201885.HKD","06821","LU0039217434.USD","LU1152091168.USD","BK1554","HK0001040168.HKD","LU1807302812.USD","LU0328353924.USD","LU0880133367.SGD","LU1719994722.HKD","LU0173614495.USD","LU1655091616.SGD","LU2294711473.HKD","SG9999001226.SGD","IE00BZ08YS42.EUR","LU1224709979.USD","LU1242518931.SGD","LU1504937902.USD","LU1023057109.AUD","BK1198","LU0543330566.HKD","LU2097828557.USD","LU0593848301.USD","LU0348816934.USD","03130","03986","BK1610","LU0106959298.USD","LU0345780521.USD","LU1988902786.USD","LU2008162690.USD","BK1515","159982","LU0049853897.USD","LU1880383440.USD","LU0082770016.SGD","LU0509642566.USD","02218","03750","02899","LU0348827113.USD","LU1720050803.USD","01108","LU0516422366.SGD","82846","LU0315179316.USD","LU0370786039.SGD","BK1110","LU1769817179.HKD","IE00BF5LJ272.USD","LU2039709279.SGD","03268","LU0287142896.SGD","BK1231","LU1675838814.USD","83130","LU0561508036.HKD","LU1242518857.USD","LU1244550494.USD","LU2226246903.HKD","LU2177674079.SGD","03678","LU2097828805.USD","LU1211504680.USD","02827","LU1769817096.USD","LU1993786604.SGD","LU0828238088.HKD","BK1592","LU1152091754.HKD","BK1181","HK0000320223.HKD","LU0348767384.USD","IE00B0169L03.USD","LU0979878070.USD","LU2476274720.SGD","LU2125910500.SGD","LU0384037296.USD","LU2242644610.SGD","02359","83188","IE00BVYPNP33.GBP","LU0431992006.USD","06745","LU0823426480.USD","BK1183","IE00B543WZ88.USD","BK1170","03308","LU0516422952.EUR","LU1794554557.SGD","BK1507","LU0456827905.SGD","LU0640798160.USD","LU0607220059.USD","LU0348825331.USD","LU1251922891.USD","LU0672654166.SGD","BK1135","LU3063872942.SGD","LU0117841782.USD","SG9999006597.SGD","LU0327786744.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121486923","title":"Yinchuan Market Regulators Roll Out Comprehensive Measures to Implement Revised Medical Device Production Quality Standards","url":"https://stock-news.laohu8.com/highlight/detail?id=1121486923","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121486923?lang=en_us&edition=fundamental","pubTime":"2026-09-03 16:00","pubTimestamp":1788422444,"startTime":"0","endTime":"0","summary":"The Yinchuan Municipal Market Supervision Administration in Ningxia is advancing a multi-pronged strategy to ensure the smooth implementation of the newly revised Medical Device Production Quality...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","159883","BK1583","BK1100","GDOC","LGHT","IEIH","HART","LNGR","MEDX","AGNG","RSPH","MDEV","BK1574","09996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128255768","title":"HK Stock Alert: Keymed Bio Surges Over 3% on Landmark Licensing Deal with Aeira","url":"https://stock-news.laohu8.com/highlight/detail?id=1128255768","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128255768?lang=en_us&edition=fundamental","pubTime":"2026-09-03 14:18","pubTimestamp":1788416295,"startTime":"0","endTime":"0","summary":"Shares of KEYMED BIO-B (02162) climbed more than 3% in Hong Kong trading, last up 2.83% at HK$79.95 with turnover reaching HK$70.71 million. The rally follows the company's announcement of an...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162","KCAI","BK1583","BK4585","BK1161","BK1574","VXUS","BK4588","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664826668","title":"Keymed Biosciences Climbs on Licensing Deal with Aeira Pte","url":"https://stock-news.laohu8.com/highlight/detail?id=2664826668","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664826668?lang=en_us&edition=fundamental","pubTime":"2026-09-03 12:31","pubTimestamp":1788409914,"startTime":"0","endTime":"0","summary":"BUZZ-Keymed Biosciences climbs on licensing deal with Aeira Pte** Shares of Keymed Biosciences Inc2162.HKclimb 2.9% in the third straight rising session to HK$80, their highest level since August 27** Keymed says it entered into an exclusive licensing agreement with pharmaceutical firm Aeira Pte, on marketing registration and commercialization of Stapokibart injection - an antibody drug for treatment of topic dermatitis, in 18 countries and regions including Southeast and Central Asia** Keymed says it will receive an upfront payment, milestone payments and commercialization milestone payments and it is entitled to receive royalties of up to a high double-digit percentage based on product net sales in the licensed territory** YTD, stock up 46.7%, Hang Seng Biotech Index.HSBIOup 10.6%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nL1N44V04C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162","BK1583","BK1161","BK1587","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128427781","title":"Clinical Data Readouts Take Center Stage as Chinese Biotech Firms Surge; CSPC Pharma Climbs Over 4% While Huabao's HK Biotech ETF Holds Key Support","url":"https://stock-news.laohu8.com/highlight/detail?id=1128427781","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128427781?lang=en_us&edition=fundamental","pubTime":"2026-09-03 11:00","pubTimestamp":1788404450,"startTime":"0","endTime":"0","summary":"Hong Kong-listed innovative drug stocks continued their upward momentum on September 3rd, with leading biotech names pushing the sector higher. CSPC Pharma and Sino Biopharmaceutical both advanced...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","IE0008368742.USD","FLHK","BK1521","LU1960683339.HKD","LU0315179316.USD","LU0880133367.SGD","01093","HK0000165453.HKD","IE00B031HY20.USD","LU0326950275.SGD","IBBQ","LU1226287792.SGD","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","159316","BK1574","LU1951186391.HKD","LU0072913022.USD","BK1161","IE0008369823.USD","06978","LU1226288253.USD","KURE","LU1993786604.SGD","LU2039709279.SGD","LNGR","IE00BZ08YT58.USD","159992","LU0314109678.HKD","LU0140636845.USD","LU0067412154.USD","MEDX","LU0501845795.SGD","LU1226288170.HKD","BK1515","IE00B5MMRT66.SGD","SG9999004220.SGD","LU1328277881.USD","LU1152091754.HKD","LU1807302812.USD","IE00B543WZ88.USD","LU1226287875.USD","LU1813983027.USD","LU1226287529.USD","LU1008478684.HKD","LU1152091168.USD","520880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664582856","title":"Keymed Biosciences Signs Licensing Deal for Kangyueda in 18 Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2664582856","media":"MT Newswires","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664582856?lang=en_us&edition=fundamental","pubTime":"2026-09-03 09:42","pubTimestamp":1788399758,"startTime":"0","endTime":"0","summary":"Keymed Biosciences  has signed a licensing agreement with Singapore-based Aeira to market and sell Kangyueda in 18 markets across Central and Southeast Asia, according to a Wednesday bourse filing.Kangyueda is approved to treat moderate-to-severe atopic dermatitis in adults, chronic rhinosinusitis with nasal polyposis and seasonal allergic rhinitis, the filing said.Under the deal, Keymed will receive an upfront payment, milestone payments upon hitting certain targets and royalties in the high-double-digit percentage range based on regional sales.Aeira will be responsible for regulatory filings and the commercialization of Kangyueda in markets including Singapore, Malaysia, the Philippines, Thailand, Kazakhstan and Uzbekistan, as well as Hong Kong and Macau.Keymed will oversee the production and timely supply of Kangyueda to Aeira.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"b010cf239ffd4765bcd3edd8f767f746","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Keymed Biosciences Signs Licensing Deal for Kangyueda in 18 Markets","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1583","BK1587","BK1161","02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664828727","title":"Is CStone Pharmaceuticals (SEHK:2616) Fully Valued On Interim Results And CS2009 Progress?","url":"https://stock-news.laohu8.com/highlight/detail?id=2664828727","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664828727?lang=en_us&edition=fundamental","pubTime":"2026-09-03 08:38","pubTimestamp":1788395893,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals (SEHK:2616) stock is in focus after the company released its 2026 interim update, highlighting fresh CS2009 clinical data, stronger pralsetinib uptake, and progress toward global Phase III trials.\nAt a latest share price of HK$6.18, CStone Pharmaceuticals has seen a 1 month share price return of 42.07% and a 90 day share price return of 23.35%. However, the 1 year total shareholder return declined 48.93%, which hints that recent clinical and interim results have...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2616/cstone-pharmaceuticals-shares/news/is-cstone-pharmaceuticals-sehk2616-fully-valued-on-interim-r","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2616/cstone-pharmaceuticals-shares/news/is-cstone-pharmaceuticals-sehk2616-fully-valued-on-interim-r","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","BK1161","BK1574","PRGS","BK4097","02616","LU2065732104.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664440588","title":"Akeso - Ivonescimab Meets Os Key Secondary Endpoint in Harmoni-2 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2664440588","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664440588?lang=en_us&edition=fundamental","pubTime":"2026-09-03 07:02","pubTimestamp":1788390131,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nFWN44U147:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KURE","LU0348827113.USD","BK1574","IE00BPRC5H50.USD","IE00B5MMRT66.SGD","LU0348825331.USD","LU0561508036.HKD","LU0348766576.USD","LU2476274720.SGD","LU0417516571.SGD","LU2488822045.USD","LU2778985437.USD","LU0634319403.HKD","BK1161","09926","LU0348783233.USD","LU1720050803.USD","LU2476274308.USD","LU1961090484.USD","LU0417516902.SGD","LU0417516738.SGD","LU2399975544.HKD","LU0348735423.USD","IE00B543WZ88.USD","LU1794554557.SGD","LU0540923850.HKD","LU0348767384.USD","LU0348784397.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":12,"pageCount":10,"totalSize":238,"code":"91000000","status":"200"}]}}